Immunotherapy drug outperforms chemo in latest trial
A recent study comparing the immunotherapy drug pembrolizumab to chemotherapy could alter more than 30 years of practice in lung cancer treatment.
The clinical trial, known as Keynote-024 (KN-024), showed pembrolizumab’s superiority in preventing cancer progression and prolonging the lives of previously untreated patients with non-small cell lung cancer (NSCLC).
.jpg)
.jpg)
